drugset
drugset / Trial / NCT01486381

Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes

NCT01486381 ↗

Phase 3 Completed 22 enrolled Novo Nordisk A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This trial is conducted in South Africa. The aim of this trial is to investigate Long term safety of biphasic insulin aspart 30 in juveniles with type 1 diabetes previously treated in trial BIAsp-1240.

Timeline

Start
2002-03-20
Primary completion
2003-05-30
Completion
2003-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic insulin aspart Protein / enzyme biologic — Subcutaneous

Indications

type 1 diabetes mellitus